Diagnosis Curesponse Secures $6 Million Series a for Breakthrough Precision Medicine AIT News Desk Jun 5, 2020 Curesponse Is a Cancer Precision Medicine Company Whose Platform, Cresponse, Accurately and Quickly Predicts a Patient's Response to Cancer Treatment.…